We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene Showcases All-in-One Platform for Molecular Diagnostic Testing for Infectious Diseases

By LabMedica International staff writers
Posted on 25 Apr 2022
Image: All-in-One Platform performs molecular diagnostic tests for infectious diseases (Photo courtesy of Seegene)
Image: All-in-One Platform performs molecular diagnostic tests for infectious diseases (Photo courtesy of Seegene)

Seegene, Inc. (Seoul, Korea) showcased its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022).

ECCMID is the world’s premier clinical microbiology & infectious diseases event that brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program. During this event, Seegene showcased AIOS – its first fully automated MDx system. AIOS provides high-throughput real-time PCR workflow starting from nucleic acid extraction, then, real-time PCR, and finally result interpretation. AIOS is a fully automated syndromic MDx system designed in a modular concept while it compiles Seegene’s cutting-edge high multiplex real-time PCR technologies.

A noteworthy feature of AIOS is that its MDx system is composed of independent and detachable modules together with its proprietary SW architecture. Unlike others’ single-body system, AIOS is designed with an extraction/liquid handler and PCR instrument being integrated with an in-house developed robotic arm module. Hospitals and laboratories can either purchase the full package of ‘AIOS’ system or integrate their existing instruments on-site if they already have Seegene’s liquid handler and real-time PCR instrument.

Some of its other highlights include: ‘high-throughput automated syndromic MDx system’. It also adopts a variety of Seegene’s assays that are currently available on the market, which allows for symptom-based tests. And finally, it can identify the exact cause of a specific symptom with a single tube, which will enable both cost- and time- effective tests. The AIOS is ideal for small-to-medium sized hospitals due to its unique modular and assay features.

Related Links:
Seegene, Inc. 

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Automatic CLIA Analyzer
Shine i6000
New
Clinical Informatics Platform
CLARION™

Channels

Molecular Diagnostics

view channel
Image: A new CRISPR-based technique enables simultaneous detection of multiple pathogens in a single test (photo courtesy of Shutterstock)

CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously

Respiratory virus co-circulation complicates differential diagnosis, as overlapping symptoms can obscure etiology. Multiplex testing typically depends on multiple enzymes or fluorophores and multistep... Read more

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more